COVID-19

News

The unprecedented challenge of pricing a coronavirus vaccine

NIAID drops Lilly antibody from ACTIV-3 COVID-19 trial

Eli Lilly says no more patients will be treated with its COVID-19 therapy bamlanivimab in a trial run by the US National Institute of Allergy and Infectious Diseases (NIAID), as results to

News

Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sale...

Novartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new drugs like gene therapy Zolgensma gathered pace.

News

BioSig abandons COVID-19 drug trial on safety concerns

US biotech BioSig Technologies has abandoned a phase 2 trial of its antiviral drug merimepodib with Gilead’s Veklury in severe COVID-19 patients, after concluding the safety of the combinat

News

Convalescent plasma misses the mark in phase 2 trial

Hopes that antibody-laden plasma taken from recovered COVID-19 patients could lessen the severity of the disease in others have taken a knock.

News

Coronavirus vaccine: how pharma is picking up the pace

AZ, J&J COVID-19 vaccine trials okay to restart in US

US trials of AstraZeneca’s experimental COVID-19 vaccine AZD1222 have been cleared to restart by the FDA, several weeks after testing was suspended following a serious adve

News

Moderna nears COVID-19 vaccine finish line as it wraps up st...

Moderna is close to completing its phase 3 trial of COVID-19 vaccine candidate mRNA-1273 after completing recruitment of the 30,000 subjects in the trial.

NIAID drops Lilly antibody from ACTIV-3 COVID-19 trial

Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sale...

BioSig abandons COVID-19 drug trial on safety concerns

Convalescent plasma misses the mark in phase 2 trial

AZ, J&J COVID-19 vaccine trials okay to restart in US

Moderna nears COVID-19 vaccine finish line as it wraps up st...

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

COVID-19

Editor's Picks